Company Of The Day: Medtronic

MDT: Medtronic logo


Medtronic (NYSE:MDT) posted a mixed set of Q3 FY’22 results. While revenues missed expectations, remaining roughly flat year-over-year at $7.8 billion, adjusted EPS was in-line with estimates at $1.37. Guidance for Q4 was also in-line with estimates.


Relevant Articles
  1. Should You Buy Medtronic Stock At $80?
  2. Will Medtronic Stock See Higher Levels Post Q2 Results?
  3. Medtronic Stock Is A Better Pick Over This Pharmaceuticals Bellwether
  4. Should You Buy Medtronic Stock Around $90?
  5. What To Expect From Medtronic’s Q1?
  6. Will Medtronic Stock See Higher Levels?

The sales of some devices, such as its pelvic health products were impacted as the surge in omicron virus cases resulted in deferred procedures in Q3. However, the company says that it is seeing improving volumes with demand for its heart devices remaining strong.

So What?

Medtronic stock gained almost 3% in Tuesday’s trading.

See Our Complete Analysis For Medtronic

What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since the end of 2016.

Returns Feb 2022
MTD [1]
YTD [1]
Total [2]
 MDT Return 0% 0% 46%
 S&P 500 Return -5% -10% 92%
 Trefis MS Portfolio Return -3% -12% 246%

[1] Month-to-date and year-to-date as of 2/23/2022
[2] Cumulative total returns since the end of 2016

Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates